Prometheus Biosciences
(NASDAQ) RXDX
Prometheus Biosciences Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$4.00M
Net Income (TTM)
$149.13M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
RXDX News
RXDX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Prometheus Biosciences
Industry
Biotechnology
Sector
Health CareEmployees
97
CEO
Mark C. Mckenna, MBA
Headquarters
San Diego, CA 92121, US
RXDX Financials
Key Financial Metrics (TTM)
Gross Margin
100%
Operating Margin
-21%
Net Income Margin
-21%
Return on Equity
-31%
Return on Capital
-20%
Return on Assets
-19%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$6.81M
Operating Income
$145.78M
EBITDA
$145.15M
Operating Cash Flow
$123.25M
Capital Expenditure
$2.70M
Free Cash Flow
$125.96M
Cash & ST Invst.
$695.75M
Total Debt
$29.54M
Prometheus Biosciences Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$1.10M
-71.8%
Gross Profit
$1.10M
-71.8%
Gross Margin
100.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
97
N/A
Net Income
$40.88M
-27.6%
EBITDA
$48.47M
-51.6%
Quarterly Fundamentals
Net Cash
$684.21M
+222.1%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
N/A
Long Term Debt
$25.98M
+89.2%
Short Term Debt
$3.48M
+291.1%
Return on Assets
-19.14%
N/A
Return on Invested Capital
-20.30%
N/A
Free Cash Flow
$40.07M
-32.1%
Operating Cash Flow
$39.54M
-34.6%